Bamco Inc. NY Has $89.27 Million Stock Position in Repligen Corporation $RGEN

Bamco Inc. NY boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 42.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 544,779 shares of the biotechnology company’s stock after purchasing an additional 163,101 shares during the quarter. Bamco Inc. NY’s holdings in Repligen were worth $89,267,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the 3rd quarter worth $29,000. Bayforest Capital Ltd acquired a new position in shares of Repligen during the fourth quarter valued at about $32,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen during the fourth quarter valued at about $33,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen in the fourth quarter valued at about $36,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

NASDAQ RGEN opened at $133.55 on Thursday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.53 billion, a P/E ratio of 148.39, a PEG ratio of 2.54 and a beta of 1.09. The company’s 50-day simple moving average is $121.10 and its 200 day simple moving average is $136.86.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company earned $0.39 earnings per share. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on RGEN. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th. UBS Group reduced their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Roth Mkm assumed coverage on Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 target price for the company. Finally, Canaccord Genuity Group reduced their target price on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.